title: Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy.
abstract: The impact of highly active antiretroviral treatment (HAART) on anti-human immunodeficiency virus (HIV) cytotoxic T lymphocytes (CTL) was studied in 17 patients with recent symptomatic HIV-1 primary infection receiving triple combination therapy. Anti-HIV CTL were initially detected in 15 patients. In 6, CTL disappeared rapidly and persistently after initiation of therapy. Most of them had a rapid and sustained decrease in plasma HIV RNA to undetectable levels. Conversely, in 6 other patients, CTL remained detectable, which was associated with a less efficient control of viral replication. In 3 others, CTL disappeared only transiently, without clear correlation with the virologic profile. Altogether, despite individual variations, there was a positive correlation between viral replication and anti-HIV-1 cytotoxicity in most subjects, suggesting that the persistence of viral antigens is the main determinant for the maintenance of CTL activity. This raises the question of the potential benefit of anti-HIV CTL induction by immunotherapy in acute seroconverters treated by HAART.
authors.affiliation: Laboratoire d'Immunologie des Pathologies Infectieuses et Tumorales, Unité 445 de l'Institut National de la Santé et de la Recherche Médicale, Université René Descartes, Hôpital Cochin, Paris, France. dalod@icgm.cochin.inserm.fr
authors.forename: M
authors.initials: M
authors.lastname: Dalod
authors.forename: M
authors.initials: M
authors.lastname: Harzic
authors.forename: I
authors.initials: I
authors.lastname: Pellegrin
authors.forename: B
authors.initials: B
authors.lastname: Dumon
authors.forename: B
authors.initials: B
authors.lastname: Hoen
authors.forename: D
authors.initials: D
authors.lastname: Sereni
authors.forename: J C
authors.initials: JC
authors.lastname: Deschemin
authors.forename: J P
authors.initials: JP
authors.lastname: Levy
authors.forename: A
authors.initials: A
authors.lastname: Venet
authors.forename: E
authors.initials: E
authors.lastname: Gomard
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002461:Cell Line, Transformed; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D015497:HIV-1 / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D012367:RNA, Viral / Q000097:blood; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D019438:Ritonavir / Q000627:therapeutic use; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D019562:Viral Load; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D015215:Zidovudine; D019438:Ritonavir